Table 4. Poor prognostic factors of HCC after non-curative therapy.
| Variable | Case No. | Univariate analysis |
Multivariate analysis |
||
|---|---|---|---|---|---|
| Hazard ratio (95% CI) | p | Hazard ratio (95% CI) | p | ||
| Age > 65/≤65 years | 329/275 | 0.758(0.623–0.922) | 0.005 | ||
| Sex male/female | 476/128 | 1.459(1.136–1.874) | 0.003 | 1.487(1.150–1.924) | 0.003 |
| HBsAg positive/negative | 329/273 | 1.510(1.238–1.843) | <0.001 | ||
| Anti-HCV positive/negative | 171/432 | 0.804(0.645–1.000) | 0.050 | ||
| Albumin ≤4/>4 g/dL | 520/83 | 1.776(1.312–2.405) | <0.001 | 1.773(1.293–2.432) | <0.001 |
| Bilirubin >1.6/≤1.6 mg/dL | 185/419 | 1.799(1.464–2.210) | <0.001 | 1.875(1.508–2.332) | <0.001 |
| ALT > 40/≤40 U/L | 373/231 | 1.227(1.001–1.505) | 0.049 | ||
| AST > 45/≤45 U/L | 447/144 | 1.872(1.455–2.409) | <0.001 | ||
| Platelet ≤105/>105/mm3 | 191/413 | 1.025(0.831–1.265) | 0.818 | ||
| PT INR > 1.1/≤1.1 | 330/274 | 1.206(0.990–1.468) | 0.063 | ||
| Ascites (yes/no) | 244/360 | 2.851(2.334–3.482) | <0.001 | ||
| AFP > 20/≤20 ng/ml | 427/176 | 2.360(1.855–3.003) | <0.001 | 1.975(1.532–2.546) | <0.001 |
| Multiple tumor (yes/no) | 353/251 | 1.178(0.965–1.439) | 0.108 | ||
| Tumor size > 3/≤3 cm | 503/101 | 3.112(2.242–4.318) | <0.001 | 2.615(1.855–3.688) | <0.001 |
| Vascular invasion (yes/no) | 254/350 | 3.076(2.510–3.771) | <0.001 | 2.458(1.978–3.054) | <0.001 |
| EGV (yes/no) | 337/267 | 1.492(1.221–1.822) | <0.001 | 1.254(1.013–1.553) | 0.038 |
Abbreviations: CI: confidence interval; HBsAg: hepatitis B surface antigen; HCV: hepatitis C virus; MELD: model for end-stage liver disease; ALT: alanine aminotransferase; AST: aspartate aminotransferase; Alk-P: alkaline phosphate; PT INR: prothrombin time international normalized ratio; AFP: alpha-fetoprotein; EGV: esophagogastric varices.